An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I

Documenti analoghi

• A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II
  di: Snezana Milanovic, et al.
  Pubblicazione: (2025)
• Efficacy and safety of continuous glucose monitoring on glycaemic control in patients with chronic pancreatitis and insulin‐treated diabetes: A randomised, open‐label, crossover trial
  di: Line Davidsen, et al.
  Pubblicazione: (2025)
• Evaluation of OCT2‐mediated drug–drug interactions between ulotaront and metformin in subjects with schizophrenia
  di: Guangqing Xiao, et al.
  Pubblicazione: (2024)
• Low‐calorie, high‐protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity
  di: Carmen Rodrigo‐Carbó, et al.
  Pubblicazione: (2024)
• The effects of antihypertensive drugs on glucose metabolism
  di: Zhe Li, et al.
  Pubblicazione: (2024)